Join to View Full Profile
3485 Independence DrHomewood, AL 35209
Phone+1 205-930-0920
Fax+1 205-445-0115
Dr. Deguenther is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of TennesseeResidency, Urology, 1991 - 1995- University of TennesseeResidency, Surgery, 1989 - 1991
Medical College of Georgia at Augusta UniversityClass of 1989
Certifications & Licensure
AL State Medical License 1995 - 2025
TN State Medical License 1990 - 1995
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2012-2013
Clinical Trials
- Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG Start of enrollment: 2015 Aug 01
- Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients Start of enrollment: 2016 Dec 01
- Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer Start of enrollment: 2017 Sep 26
Publications & Presentations
PubMed
- 5 citationsA phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patientsNeal D. Shore, Ivan Mincik, Mark DeGuenther, Vladimir Student, Mindaugas Jievaltas
World Journal of Urology. 2020-01-01 - 15 citationsSelf-Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on b...William E. Grizzle, Rick A. Kittles, Soroush Rais-Bahrami, Ebony Shah, George W. Adams
Cancer Medicine. 2019-11-01 - 39 citationsTwo-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements SustainedPeter J. Gilling, Neil Barber, Mohamed Bidair, Paul Anderson, Mark A. Sutton
Advances in Therapy. 2019-04-26
Journal Articles
- Symptom Relief and Anejaculation After Aquablation or TURP: Subgroup Analysis from a Blinded Randomized TrialAlexis E Te, Mark Plante, Barrett Cowan, Claus Roehrborn, Mohamed Bidair, Leo Doumanian, Andrew Arther, Gopal Badlani, Mark DeGuenther, Mark Sutton, BJU International
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
